{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:37:08Z","timestamp":1792978628244,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Li Huanying Medical Foundation, BeiGene, Ltd., and National Key Technologies R&D Program"},{"DOI":"10.13039\/501100005024","name":"Beijing Postdoctoral Research Foundation","doi-asserted-by":"publisher","award":["2023-ZZ-038"],"award-info":[{"award-number":["2023-ZZ-038"]}],"id":[{"id":"10.13039\/501100005024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41591-024-03360-5","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:02:43Z","timestamp":1736139763000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9126-3281","authenticated-orcid":false,"given":"Yingchi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1945-2870","authenticated-orcid":false,"given":"Kai","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-3028","authenticated-orcid":false,"given":"Guole","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2020-5161","authenticated-orcid":false,"given":"Jiaolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-1443","authenticated-orcid":false,"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-3481","authenticated-orcid":false,"given":"Aiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-1227","authenticated-orcid":false,"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-6520","authenticated-orcid":false,"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-6821","authenticated-orcid":false,"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"3360_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3360_CR2","first-page":"3003","volume":"109","author":"Q Wei","year":"2023","unstructured":"Wei, Q. et al. Incidence, prevention, risk factors, and prediction of venous thromboembolism in Chinese patients after colorectal cancer surgery: a prospective, multicenter cohort study. Int. J. Surg. 109, 3003\u20133012 (2023).","journal-title":"Int. J. Surg."},{"key":"3360_CR3","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3360_CR4","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865\u20131874 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3360_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"3360_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"3360_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/jgo.2018.10.01","volume":"10","author":"V Ostwal","year":"2019","unstructured":"Ostwal, V. et al. Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. J. Gastrointest. Oncol. 10, 19\u201329 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"3360_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11525-7","volume":"23","author":"K Ni","year":"2023","unstructured":"Ni, K. et al. Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone. BMC Cancer 23, 1013 (2023).","journal-title":"BMC Cancer"},{"key":"3360_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/annonc\/mdx790","volume":"29","author":"T Kordbacheh","year":"2018","unstructured":"Kordbacheh, T., Honeychurch, J., Blackhall, F., Faivre-Finn, C. & Illidge, T. Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms. Ann. Oncol. 29, 301\u2013310 (2018).","journal-title":"Ann. Oncol."},{"key":"3360_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","volume":"9","author":"Z Lin","year":"2021","unstructured":"Lin, Z. et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J. Immunother. Cancer 9, e003554 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"3360_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01673-6","volume":"15","author":"A Shamseddine","year":"2020","unstructured":"Shamseddine, A. et al. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Radiat. Oncol. 15, 233 (2020).","journal-title":"Radiat. Oncol."},{"key":"3360_CR12","first-page":"3511","volume":"39","author":"L Salvatore","year":"2021","unstructured":"Salvatore, L. et al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study. Ann. Oncol. 39, 3511 (2021).","journal-title":"Ann. Oncol."},{"key":"3360_CR13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","volume":"28","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Clin. Cancer Res. 28, 1136\u20131146 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3360_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1057947","volume":"13","author":"J Gao","year":"2023","unstructured":"Gao, J. et al. Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. Front. Oncol. 13, 1057947 (2023).","journal-title":"Front. Oncol."},{"key":"3360_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","volume":"9","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct. Target Ther. 9, 56 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"3360_CR16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/bjs.8702","volume":"99","author":"ST Martin","year":"2012","unstructured":"Martin, S. T., Heneghan, H. M. & Winter, D. C. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br. J. Surg. 99, 918\u2013928 (2012).","journal-title":"Br. J. Surg."},{"key":"3360_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","volume":"11","author":"M Maas","year":"2010","unstructured":"Maas, M. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11, 835\u2013844 (2010).","journal-title":"Lancet Oncol."},{"key":"3360_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","volume":"20","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi, L., Aryankalayil, M. J., Coleman, C. N. & Formenti, S. C. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20, 543\u2013557 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3360_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv. Sci. 9, e2201734 (2022).","journal-title":"Adv. Sci."},{"key":"3360_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.ijrobp.2017.07.004","volume":"99","author":"YJ Lim","year":"2017","unstructured":"Lim, Y. J. et al. Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes identified patients with poor prognosis in rectal cancer: a matched comparison analysis. Int. J. Radiat. Oncol. Biol. Phys. 99, 1216\u20131224 (2017).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"3360_CR21","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1245\/s10434-014-3584-y","volume":"21","author":"E Shinto","year":"2014","unstructured":"Shinto, E. et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann. Surg. Oncol. 21, S414\u2013S421 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"3360_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar, J. et al. Timing of rectal cancer response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16, 957\u2013966 (2015).","journal-title":"Lancet Oncol."},{"key":"3360_CR23","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin, J. et al. Multicenter, randomized, phase III trial of Short-Term Radiotherapy Plus Chemotherapy versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J. Clin. Oncol. 40, 1681\u20131692 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3360_CR24","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","volume":"7","author":"OE Rahma","year":"2021","unstructured":"Rahma, O. E. et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol. 7, 1225\u20131230 (2021).","journal-title":"JAMA Oncol."},{"key":"3360_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000807","volume":"8","author":"X He","year":"2020","unstructured":"He, X. et al. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. J. Immunother. Cancer 8, e000807 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"3360_CR26","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/cancers12123648","volume":"12","author":"B Halmos","year":"2020","unstructured":"Halmos, B. et al. A matching-adjusted indirect comparison of pembrolizumab + chemotherapy vs. nivolumab + ipilimumab as first-line therapies in patients with PD-L1 TPS \u22651% metastatic NSCLC. Cancers 12, 3648 (2020).","journal-title":"Cancers"},{"key":"3360_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/CMR.0000000000000592","volume":"29","author":"U Swami","year":"2019","unstructured":"Swami, U. et al. Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. Melanoma Res. 29, 643\u2013647 (2019).","journal-title":"Melanoma Res."},{"key":"3360_CR28","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3360_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301\u20131311 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3360_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/codi.14867","volume":"22","author":"C Terzi","year":"2020","unstructured":"Terzi, C. et al. Randomized controlled trial of 8 weeks\u2019 vs 12 weeks\u2019 interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. Colorectal Dis. 22, 279\u2013288 (2020).","journal-title":"Colorectal Dis."},{"key":"3360_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/bjs.10984","volume":"105","author":"E Akgun","year":"2018","unstructured":"Akgun, E. et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br. J. Surg. 105, 1417\u20131425 (2018).","journal-title":"Br. J. Surg."},{"key":"3360_CR32","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","volume":"34","author":"JH Lefevre","year":"2016","unstructured":"Lefevre, J. H. et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J. Clin. Oncol. 34, 3773\u20133780 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3360_CR33","unstructured":"Pang, K. BioRender. BioRender http:\/\/www.BioRender.com\/b53j971 (2021)."},{"key":"3360_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton, D. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J. Clin. Oncol. 41, 1541\u20131552 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3360_CR35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0140-6736(86)92612-7","volume":"2","author":"P Quirke","year":"1986","unstructured":"Quirke, P., Durdey, P., Dixon, M. F. & Williams, N. S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Lancet 2, 996\u2013999 (1986).","journal-title":"Lancet"},{"key":"3360_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju248","volume":"106","author":"A Trakarnsanga","year":"2014","unstructured":"Trakarnsanga, A. et al. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J. Natl Cancer Inst. 106, dju248 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"3360_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/annonc\/mdy143","volume":"29","author":"E Fokas","year":"2018","unstructured":"Fokas, E. et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO\/ARO\/AIO-04 randomized phase III trial. Ann. Oncol. 29, 1521\u20131527 (2018).","journal-title":"Ann. Oncol."},{"key":"3360_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069499","volume":"13","author":"K Pang","year":"2023","unstructured":"Pang, K. et al. Long-course chemoradiation plus concurrent\/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). BMJ Open 13, e069499 (2023).","journal-title":"BMJ Open"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03360-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:02:31Z","timestamp":1739901751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03360-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3360"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03360-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}